# Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4

> **NCT01006031** · PHASE2,PHASE3 · COMPLETED · sponsor: **Sociedad Andaluza de Enfermedades Infecciosas** · enrollment: 25 (actual)

## Conditions studied

- Liver Cirrhosis
- Hepatitis C Virus
- HIV Infection

## Interventions

- **DRUG:** Pegylated interferon alfa-2a and Ribavirin

## Key facts

- **NCT ID:** NCT01006031
- **Lead sponsor:** Sociedad Andaluza de Enfermedades Infecciosas
- **Sponsor class:** NETWORK
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2011-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01006031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01006031, "Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01006031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*